Remove Blood Pressure Remove Hypertension Remove Kidney Disease
article thumbnail

Oral nitrate-reducing bacteria as potential probiotics for blood pressure homeostasis

Frontiers in Cardiovascular Medicine

Hypertension is a leading cause of morbidity and mortality worldwide and poses a major risk factor for cardiovascular diseases and chronic kidney disease.

article thumbnail

One Injection of Novel Drug Cuts Systolic Blood Pressure by Up to 12 mmHg

DAIC

Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in blood pressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In

article thumbnail

EHR Alerts Trigger Primary Care Clinics to Improve Hypertension Care in CKD

Med Page Today

(MedPage Today) -- A computerized clinical decision support (CDS) tool for primary care helped lower blood pressure (BP) in patients with chronic kidney disease (CKD) and uncontrolled hypertension, a cluster-randomized trial found. When primary.

article thumbnail

Abstract 4143897: Monocyte regulation of magnesium during salt sensitivity of blood pressure

Circulation

Background:Dietary magnesium (Mg+2) deficiency has been linked to hypertension, chronic kidney disease, and cardiovascular disease. High sodium intake and reduced dietary Mg+2consumption are associated with elevated blood pressure.

article thumbnail

Prognostic Value of Nighttime Double Product in Nondialysis Chronic Kidney Disease With Hypertension

Journal of the American Heart Association

BackgroundBoth nighttime systolic blood pressure and pulse rate are associated with adverse outcomes in patients with chronic kidney disease (CKD). However, nighttime double product (DP), which is the product of nighttime systolic blood pressure and pulse rate, has not yet been investigated in this context.

article thumbnail

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

DAIC

The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. Orchestra BioMed and Medtronic, Inc. Kowal, M.D.,

Pacemaker 105
article thumbnail

Clinical Decision Support for Hypertension Management in CKD

American College of Cardiology

Does a computerized clinical decision support (CDS) system based on behavioral economic principles and human-centered design lead to a decrease in systolic blood pressure (SBP) in patients with chronic kidney disease (CKD) and uncontrolled hypertension?